The Pulmonary Vascular Research Institute (PVRI) www.pvrinstitute.org and industry partners have embarked on a co-ordinated effort of humanitarian support for patients with the life-threatening condition of pulmonary arterial hypertension (PAH).
For PAH patients that are already established on most therapies, it is essential to continue a course of treatment to improve both their quality and quantity of life.
Industry partners have responded to calls of support from the PVRI and will donate sufficient quantities of drugs to cover the needs of patients via support from the Cardiac Society of Poland. All parties are now working towards the delivery of these effective therapies to those living in Ukraine or crossing the border into Poland as refugees.
The PVRI’s established collaborative industry partnership has co-ordinated this effort through its Access to Care and patient engagement initiatives, in collaboration with Dr Ewa Mroczec and Dr Adam Torbicki in Poland, and Dr Yuriy Sirenko in Ukraine. The organisation will continue to utilise its network of key stakeholders to provide support, where possible, to all patients affected by the supply disruption.
More on PAH and Ukraine
The PHA UK caught up with Dr Joanna Pepke-Zaba on 18 March, who has strong links to European efforts to get help to people affected by this disease. Dr Pepke-Zaba, who is based in Cambridge, joined the PHA from a conference in Switzerland for a special episode of their podcast, EmPHAsis on Air, that aims to shed some light on this aspect of the humanitarian crisis.